It’s still early days for VC in China’s early stage biopharmas
By Shannon Ellis
Wednesday, March 26, 2014
SHANGHAI – There are more bees than flowers in the China biopharma space, with venture capital (VC) interest outstripping the number of early stage companies with novel biologics to develop.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.